Reference

1. Pfizer Inc. LITFULO™ (ritlecitinib) capsules, for oral use: US prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf. Accessed 26 Jul 2023.
2. Pfizer. FDA approves Pfizer’s LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata [media release]. 23 June 2023. https://www.pfizer.com/news/press- release/press-release-detail/fda-approves pfizers-litfulotm-ritlecitinib-adults
3. Pfizer Japan Inc. [Oral JAK3/TEC family kinase inhibitor "Litfulo® capsules 50mg (generic name: ritlecitinib tosylate)" obtained manufacturing and marketing approval to meet the unmet needs of patients with alopecia areata] [media release]. 26 Jun 2023. https://www.pfizer.co.jp/pfizer/company/press/2023/2023-06-26.
4. European Medicines Agency. CHMP summary of positive opinion for Litfulo (ritlecitinib). 2023. https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-litfulo_en.pdf. Accessed 26 Jul 2023.
5. K. Triyangkulsri, P. Suchonwanit. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther. 2018 Jul 27;12:2323-2335. doi: 10.2147/DDDT.S172638. eCollection 2018.
6. Xu H, Jesson MI, Seneviratne UI, et al. PF-06651600, a dual JAK3/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6):1235?1242. doi: 10.1021/acschembio.9b00188.
7. [Telliez JB, Dowty ME, Wang L, et al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol. 2016;11(12):3442?3451. doi: 10.1021/acschembio.6b00677. [PubMed] [CrossRef] [Google Scholar]PubMed] [CrossRef] [Google Scholar]
8. Liu J, Solan R, Wolk R, et al. Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants. Br J Clin Pharmacol. 2023;89(7):2208?2215. doi: 10.1111/bcp.15695. [PubMed] [CrossRef] [Google Scholar]
9. D. Yan, H. Fan, M. Chen, L. Xia, S. Wang, W. Dong, Q. Wang, S. Niu, H. Rao, L. Chen, X. Nie, Y. Fang, ?The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies?. Front Pharmacol. 2022 Aug 24;13:950450. doi:10.3389/fphar.2022.950450.
10. K. Triyangkulsri, P. Suchonwanit. ?Role of janus kinase inhibitors in the treatment of alopecia areata?. Drug Des Devel Ther. 2018 Jul 27;12:2323-2335. doi: 10.2147/DDDT.S172638. eCollection 2018.
11. FDA Approved Drug Products: LITFULO (ritlecitinib) capsules for oral use (June 2023)
12. https://cts.businesswire.com/ct/CT?id=smartlink&url=https://www.fda.gov/fil es/about fda/published/Alopecia-Areata--The-Voice-of-the- Patient.pdf&esheet=53556598&newsitemid=20230918672148&lan=en- US&anchor=https://www.fda.gov/files/about fda/published/Alope cia-Areata--The-Voice-of-the-Patient.pdf&index=11&md5=0d566f90c35ff968bee9b99fd37d280b
13. Pfizer, June 23 2023,1 July 2023, (labeling.pfizer.com/ShowLabeling.aspx?id=19638
14. Drug bank, 20 may 2019,3 July 2023 Ritlecitinib: Uses, Interactions, Mechanism of Action | DrugBank Online accession number-DB14924 1
15. King B, Soung J, Tziotzios C, et al. Integrated safety analysis of ritlecitinib for the treatment of alopecia areata (AA) from the phase 2 and phase 3 ALLEGRO clinical trial program [abstract no. T4 plus oral presentation]. In: European Hair Research Society Meeting. 2023.
16. Soung J, King B, Tziotzios C, et al. Integrated safety analysis of ritlecitinib in adolescent patients with alopecia areata from the randomized, placebo-controlled ALLEGRO phase 2b/3 and ongoing open-label phase 3 ALLEGRO-LT studies [abstract no. 43117 plus poster]. In:American Academy of Dermatology Annual Meeting. 2023.
17. King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b?3 trial. Lancet. 2023;401(10387):1518?1529. doi: 10.1016/S0140 6736(23)00222-2. [PubMed] [CrossRef] [Google Scholar]
18. Mesinkovska N, Shapiro J, King B. Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF- 06651600) in patients with alopecia areata over 48 weeks: results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial [abstract no. 33183] J Am Acad Dermatol. 2022;87(3 Suppl.):AB54. doi: 10.1016/j.jaad.2022.06.249. [CrossRef] [Google Scholar]
19. King B, Mirmirani P, Lo Sicco K, et al. Individual SALT score trajectories of de novo patients with alopecia areata (AA) treated with ritlecitinib in the ongoing phase 3, long-term, open-label ALLEGRO-LT study [abstract no. LB1697]. In: First International Societies for Investigative Dermatology (ISID) Meeting. 2023